相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Functional evidence for biased inhibition of G protein signaling by YM-254890 in human coronary artery endothelial cells
Qianman Peng et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2021)
GLP-1 Val8: A Biased GLP-1R Agonist with Altered Binding Kinetics and Impaired Release of Pancreatic Hormones in Rats
Wijnand J. C. van der Velden et al.
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2021)
Exploring G Protein-Coupled Receptor Signaling in Primary Pancreatic Islets
Juliane Roethe et al.
BIOLOGICAL PROCEDURES ONLINE (2020)
Morphine-induced respiratory depression is independent of β-arrestin2 signalling
Andrea Kliewer et al.
BRITISH JOURNAL OF PHARMACOLOGY (2020)
Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens
Juan Pablo Frias et al.
DIABETES OBESITY & METABOLISM (2020)
Activation of the GLP-1 receptor by a non-peptidic agonist
Peishen Zhao et al.
NATURE (2020)
Super-resolution microscopy compatible fluorescent probes reveal endogenous glucagon-like peptide-1 receptor distribution and dynamics
Julia Ast et al.
NATURE COMMUNICATIONS (2020)
β-Arrestin-2 BRET Biosensors Detect Different β-Arrestin-2 Conformations in Interaction with GPCRs
Atsuro Oishi et al.
ACS SENSORS (2020)
Signalling, trafficking and glucoregulatory properties of glucagon-like peptide-1 receptor agonists exendin-4 and lixisenatide
Philip Pickford et al.
BRITISH JOURNAL OF PHARMACOLOGY (2020)
Effects of Sustained Treatment With Lixisenatide on Gastric Emptying and Postprandial Glucose Metabolism in Type 2 Diabetes: A Randomized Controlled Trial
Christopher K. Rayner et al.
DIABETES CARE (2020)
Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists
Alexander Gillis et al.
SCIENCE SIGNALING (2020)
Brain Endothelial Cells Regulate Glucagon-Like Peptide 1 Entry Into the Brain via a Receptor-Mediated Process
Zhuo Fu et al.
FRONTIERS IN PHYSIOLOGY (2020)
Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors
Elita Yuliantie et al.
BIOCHEMICAL PHARMACOLOGY (2020)
Disconnect between signalling potency and in vivo ef fi cacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists
Maria Lucey et al.
MOLECULAR METABOLISM (2020)
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Francis S. Willard et al.
JCI INSIGHT (2020)
Evaluation of biased agonism mediated by dual agonists of the GLP-1 and glucagon receptors
Sanaz Darbalaei et al.
BIOCHEMICAL PHARMACOLOGY (2020)
How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Ricardo J. Samms et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2020)
Corrination of a GLP-1 Receptor Agonist for Glycemic Control without Emesis
Tito Borner et al.
CELL REPORTS (2020)
Differential GLP-1R Binding and Activation by Peptide and Non-peptide Agonists
Xin Zhang et al.
MOLECULAR CELL (2020)
Critical Assessment of G Protein-Biased Agonism at the μ-Opioid Receptor
Alexander Gillis et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2020)
Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism
Elizabeth A. Killion et al.
NATURE COMMUNICATIONS (2020)
Alleviation of Depression by Glucagon-Like Peptide 1 Through the Regulation of Neuroinflammation, Neurotransmitters, Neurogenesis, and Synaptic Function
Young-Kook Kim et al.
FRONTIERS IN PHARMACOLOGY (2020)
GLP-1 receptor agonists in the treatment of type 2 diabetes-state-of-the-art
Michael A. Nauck et al.
MOLECULAR METABOLISM (2020)
Gs/Gq signaling switch in β cells defines incretin effectiveness in diabetes
Okechi S. Oduori et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Incretin Hormones and Type 2 Diabetes-Mechanistic Insights and Therapeutic Approaches
Geke Aline Boer et al.
BIOLOGY-BASEL (2020)
Spatiotemporal GLP-1 and GIP receptor signaling and trafficking/recycling dynamics induced by selected receptor mono- and dual-agonists
Aaron Novikoff et al.
MOLECULAR METABOLISM (2020)
Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist
Takahiro Kawai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events
Ildiko Lingvay et al.
BMJ OPEN DIABETES RESEARCH & CARE (2020)
Ligand-Specific Factors Influencing GLP-1 Receptor Post-Endocytic Trafficking and Degradation in Pancreatic Beta Cells
Zijian Fang et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
The Influence of Peptide Context on Signaling and Trafficking of Glucagon-like Peptide-1 Receptor Biased Agonists
Zijian Fang et al.
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2020)
Semaglutide lowers body weight in rodents via distributed neural pathways
Sanaz Gabery et al.
JCI INSIGHT (2020)
Novel fatty chain-modified GLP-1R G-protein biased agonist exerts prolonged anti-diabetic effects through targeting receptor binding sites (Publication with Expression of Concern. See vol. 12, pg. 33348, 2022)
Maorong Wang et al.
RSC ADVANCES (2020)
A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials
Joachim Tillner et al.
DIABETES OBESITY & METABOLISM (2019)
The Discovery and Development of Liraglutide and Semaglutide
Lotte Bjerre Knudsen et al.
FRONTIERS IN ENDOCRINOLOGY (2019)
Impact of Substitution Registry on the Receptor-Activation Profiles of Backbone-Modified Glucagon-like Peptide-1 Analogues
Brian P. Cary et al.
CHEMBIOCHEM (2019)
Clinical factors associated with the occurrence of nausea and vomiting in type 2 diabetes patients treated with glucagon-like peptide-1 receptor agonists
Megumi Shiomi et al.
JOURNAL OF DIABETES INVESTIGATION (2019)
Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake
Alice E. Adriaenssens et al.
CELL METABOLISM (2019)
β Cell-intrinsic β-arrestin 1 signaling enhances sulfonylurea-induced insulin secretion
Luiz F. Barella et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
O-GlcNAc Engineering of GPCR Peptide-Agonists Improves Their Stability and in Vivo Activity
Paul M. Levine et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2019)
Agonist-induced membrane nanodomain clustering drives GLP-1 receptor responses in pancreatic beta cells
Teresa Buenaventura et al.
PLOS BIOLOGY (2019)
Glucagon-like peptide 1 (GLP-1)
T. D. Mueller et al.
MOLECULAR METABOLISM (2019)
THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Catalytic receptors
Stephen P. H. Alexander et al.
BRITISH JOURNAL OF PHARMACOLOGY (2019)
THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors
Stephen P. H. Alexander et al.
BRITISH JOURNAL OF PHARMACOLOGY (2019)
Glucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases
Maddalena Grieco et al.
FRONTIERS IN NEUROSCIENCE (2019)
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Soren L. Kristensen et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Ureidopeptide GLP-1 analogues with prolonged activity in vivo via signal bias and altered receptor trafficking
Juliette Fremaux et al.
CHEMICAL SCIENCE (2019)
Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes A Systematic Review and Meta-analysis
Sean L. Zheng et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Mini G protein probes for active G protein-coupled receptors (GPCRs) in live cells
Qingwen Wan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer's disease
Andre F. Batista et al.
JOURNAL OF PATHOLOGY (2018)
MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study
Philip Ambery et al.
LANCET (2018)
Is the Quest for Signaling Bias Worth the Effort?
Terry Kenakin
MOLECULAR PHARMACOLOGY (2018)
Glucagon-like peptide 1 in health and disease
Andreas Andersen et al.
NATURE REVIEWS ENDOCRINOLOGY (2018)
Control of insulin secretion by GLP-1
Ben Jones et al.
PEPTIDES (2018)
Targeting GLP-1 receptor trafficking to improve agonist efficacy
Ben Jones et al.
NATURE COMMUNICATIONS (2018)
Lack of beta-arrestin signaling in the absence of active G proteins
Manuel Grundmann et al.
NATURE COMMUNICATIONS (2018)
Conditional and Reversible Activation of Class A and B G Protein-Coupled Receptors Using Tethered Pharmacology
Tom Podewin et al.
ACS CENTRAL SCIENCE (2018)
Glucagon-like peptide-1 receptor internalisation controls spatiotemporal signalling mediated by biased agonists
Madeleine M. Fletcher et al.
BIOCHEMICAL PHARMACOLOGY (2018)
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
Patrick M. O'Neil et al.
LANCET (2018)
Phase-plate cryo-EM structure of a biased agonist-bound human GLP-1 receptor-Gs complex
Yi-Lynn Liang et al.
NATURE (2018)
Acute and rapid degradation of endogenous proteins by Trim-Away
Dean Clift et al.
NATURE PROTOCOLS (2018)
Mechanisms of signalling and biased agonism in G protein-coupled receptors
Denise Wootten et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2018)
Manifold roles of beta-arrestins in GPCR signaling elucidated with siRNA and CRISPR/Cas9
Louis M. Luttrell et al.
SCIENCE SIGNALING (2018)
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
Juan Pablo Frias et al.
LANCET (2018)
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
Tamer Coskun et al.
MOLECULAR METABOLISM (2018)
Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials
Karolin Bettge et al.
DIABETES OBESITY & METABOLISM (2017)
Helixconstraints and amino acid substitution in GLP-1 increase cAMP and insulin secretion but not beta-arrestin 2 signaling
Fabien Plisson et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Liraglutide, a glucagon-like peptide-1 receptor agonist, facilitates osteogenic proliferation and differentiation in MC3T3-E1 cells through phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT), extracellular signal-related kinase (ERK)1/2, and cAMP/protein kinase A (PKA) signaling pathways involving β-catenin
Xuelun Wu et al.
EXPERIMENTAL CELL RESEARCH (2017)
Enhanced AMPA Receptor Trafficking Mediates the Anorexigenic Effect of Endogenous Glucagon-like Peptide-1 in the Paraventricular Hypothalamus
Ji Liu et al.
NEURON (2017)
A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus
Hannah F. Botfield et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
β-arrestin-2 is an essential regulator of pancreatic β-cell function under physiological and pathophysiological conditions
Lu Zhu et al.
NATURE COMMUNICATIONS (2017)
Using nanoBRET and CRISPR/Cas9 to monitor proximity to a genome-edited protein in real-time
Carl W. White et al.
SCIENTIFIC REPORTS (2017)
Gαs regulates Glucagon-Like Peptide 1 Receptor-mediated cyclic AMP generation at Rab5 endosomal compartment
Shravan Babu Glrada et al.
MOLECULAR METABOLISM (2017)
The dynamic plasticity of insulin production in β-cells
Brandon B. Boland et al.
MOLECULAR METABOLISM (2017)
Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes
Mirko V. Sikirica et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2017)
Systematic errors in detecting biased agonism: Analysis of current methods and development of a new model-free approach
H. Ongun Onaran et al.
SCIENTIFIC REPORTS (2017)
Synergistic effects of metformin with liraglutide against endothelial dysfunction through GLP-1 receptor and PKA signalling pathway
Jing Ke et al.
Scientific Reports (2017)
Bias Factor and Therapeutic Window Correlate to Predict Safer Opioid Analgesics
Cullen L. Schmid et al.
CELL (2017)
Characterization of signal bias at the GLP-1 receptor induced by backbone modification of GLP-1
Marlies V. Hager et al.
BIOCHEMICAL PHARMACOLOGY (2017)
Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes
Heidi Storgaard et al.
DIABETES OBESITY & METABOLISM (2017)
Knockdown of GLP-1 Receptors in Vagal Afferents Affects Normal Food Intake and Glycemia
Jean-Philippe Krieger et al.
DIABETES (2016)
TCF1 links GIPR signaling to the control of beta cell function and survival
Jonathan E. Campbell et al.
NATURE MEDICINE (2016)
On the selectivity of the Gαq inhibitor UBO-QIC: A comparison with the Gαi inhibitor pertussis toxin
Zhan-Guo Gao et al.
BIOCHEMICAL PHARMACOLOGY (2016)
The Extracellular Surface of the GLP-1 Receptor Is a Molecular Trigger for Biased Agonism
Denise Wootten et al.
CELL (2016)
β-Arrestin-Biased Agonists of the GLP-1 Receptor from β-Amino Acid Residue Incorporation into GLP-1 Analogues
Marlies V. Hager et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2016)
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
Matthew James Armstrong et al.
LANCET (2016)
The role of kinetic context in apparent biased agonism at GPCRs
Carmen Klein Herenbrink et al.
NATURE COMMUNICATIONS (2016)
The Neuroprotection of Liraglutide Against Ischaemia-induced Apoptosis through the Activation of the PI3K/AKT and MAPK Pathways
Huili Zhu et al.
SCIENTIFIC REPORTS (2016)
Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes
Chris de Graaf et al.
PHARMACOLOGICAL REVIEWS (2016)
Agonist-induced internalisation of the glucagon-like peptide-1 receptor is mediated by the G alpha(q) pathway
Aiysha Thompson et al.
BIOCHEMICAL PHARMACOLOGY (2015)
Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes The SCALE Diabetes Randomized Clinical Trial
Melanie J. Davies et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
GLP-1 stimulates insulin secretion by PKC-dependent TRPM4 and TRPM5 activation
Makoto Shigeto et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Autocrine selection of a GLP-1R G-protein biased agonist with potent antidiabetic effects
Hongkai Zhang et al.
NATURE COMMUNICATIONS (2015)
Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain
Simon C. Cork et al.
MOLECULAR METABOLISM (2015)
Functional Consequences of Glucagon-like Peptide-1 Receptor Cross-talk and Trafficking
Sarah Noerklit Roed et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Investigating G protein signalling bias at the glucagon-like peptide-1 receptor in yeast
C. Weston et al.
BRITISH JOURNAL OF PHARMACOLOGY (2014)
Identification and Characterization of GLP-1 Receptor-Expressing Cells Using a New Transgenic Mouse Model
Paul Richards et al.
DIABETES (2014)
β-Arrestin2 plays a key role in the modulation of the pancreatic beta cell mass in mice
Magalie A. Ravier et al.
DIABETOLOGIA (2014)
Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect
Stephanie Sisley et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Glucagon-like peptide-1 receptor-mediated endosomal cAMP generation promotes glucose-stimulated insulin secretion in pancreatic β-cells
Ramya S. Kuna et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2013)
Pancreatic beta-Cell Response to Increased Metabolic Demand and to Pharmacologic Secretagogues Requires EPAC2A
Woo-Jin Song et al.
DIABETES (2013)
β-Cell Specific Protein Kinase A Activation Enhances the Efficiency of Glucose Control by Increasing Acute-Phase Insulin Secretion
Kelly A. Kaihara et al.
DIABETES (2013)
Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors
Alexandra E. Butler et al.
DIABETES (2013)
Lipotoxicity disrupts incretin-regulated human β cell connectivity
David J. Hodson et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
A Simple Method for Quantifying Functional Selectivity and Agonist Bias
Terry Kenakin et al.
ACS CHEMICAL NEUROSCIENCE (2012)
Regulation of Adipocyte Formation by GLP-1/GLP-1R Signaling
Tenagne Delessa Challa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
EXENDIN-4 IMPROVED RAT CORTICAL NEURON SURVIVAL UNDER OXYGEN/GLUCOSE DEPRIVATION THROUGH PKA PATHWAY
M. -D. Wang et al.
NEUROSCIENCE (2012)
Intracellular Signals Mediating the Food Intake-Suppressive Effects of Hindbrain Glucagon-like Peptide-1 Receptor Activation
Matthew R. Hayes et al.
CELL METABOLISM (2011)
Rapid Tachyphylaxis of the Glucagon-Like Peptide 1-Induced Deceleration of Gastric Emptying in Humans
Michael A. Nauck et al.
DIABETES (2011)
Modulation of the Glucagon-Like Peptide-1 Receptor Signaling by Naturally Occurring and Synthetic Flavonoids
Denise Wootten et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Loss of βarrestin1 and βarrestin2 contributes to pulmonary hypoplasia and neonatal lethality in mice
Mingfeng Zhang et al.
DEVELOPMENTAL BIOLOGY (2010)
Exendin-4 Protects Pancreatic Beta Cells from the Cytotoxic Effect of Rapamycin by Inhibiting JNK and p38 Phosphorylation
Y. Kawasaki et al.
HORMONE AND METABOLIC RESEARCH (2010)
GLP-1 Mediates Antiapoptotic Effect by Phosphorylating Bad through a β-Arrestin 1-mediated ERK1/2 Activation in Pancreatic β-Cells
Julie Quoyer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
The G(q)/G(11)-mediated signaling pathway is critical for autocrine potentiation of insulin secretion in mice
Antonia Sassmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Comparative Effects of the Endogenous Agonist Glucagon-Like Peptide-1 (GLP-1)-(7-36) Amide and the Small-Molecule Ago-Allosteric Agent Compound 2 at the GLP-1 Receptor
Karen Coopman et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
Epac2-dependent mobilization of intracellular Ca2+by glucagon-like peptide-1 receptor agonist exendin-4 is disrupted in β-cells of phospholipase C-ε knockout mice
Igor Dzhura et al.
JOURNAL OF PHYSIOLOGY-LONDON (2010)
Allosteric Ligands of the Glucagon-Like Peptide 1 Receptor (GLP-1R) Differentially Modulate Endogenous and Exogenous Peptide Responses in a Pathway-Selective Manner: Implications for Drug Screening
Cassandra Koole et al.
MOLECULAR PHARMACOLOGY (2010)
Cav1.2 and Cav1.3 Are Differentially Coupled to Glucagon-Like Peptide-1 Potentiation of Glucose-Stimulated Insulin Secretion in the Pancreatic β-Cell Line INS-1
Sarah Melissa P. Jacobo et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
Alan Garber et al.
LANCET (2009)
Persistent cAMP-Signals Triggered by Internalized G-Protein-Coupled Receptors
Davide Calebiro et al.
PLOS BIOLOGY (2009)
Role of the cAMP sensor Epac as a determinant of KATP channel ATP sensitivity in human pancreatic β-cells and rat INS-1 cells
Guoxin Kang et al.
JOURNAL OF PHYSIOLOGY-LONDON (2008)
β-Arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic β cells
Noriyuki Sonoda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
β cell-specific deficiency of the stimulatory G protein α-subunit Gsα leads to reduced β cell mass and insulin-deficient diabetes
Tao Xie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Oxyntomodulin differentially affects glucagon-like peptide-1 receptor β-arrestin recruitment and signaling through Gαs
Rasmus Jorgensen et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
GLP-1 receptor activation improves β cell function and survival following induction of endoplasmic reticulum stress
Bernardo Yusta et al.
CELL METABOLISM (2006)
Morphine side effects in beta-arrestin 2 knockout mice
KM Raehal et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Differential activation mechanisms of Erk-1/2 and p70S6K by glucose in pancreatic β-cells
I Briaud et al.
DIABETES (2003)
Critical role of cAMP-GEFII.Rim2 complex in incretin-potentiated insulin secretion
Y Kashima et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Activation and targeting of extracellular signal-regulated kinases by β-arrestin scaffolds
LM Luttrell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Glucagon-like peptide 1 stimulates insulin gene promoter activity by protein kinase A - Independent activation of the rat insulin I gene cAMP response element
G Skoglund et al.
DIABETES (2000)
分享论文
